Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice
| Autor: | Santiago Aguín, María Victoria Baeza-Nadal, T. Sauri, Francisco García-Navalón, Dulce Rodríguez, Ana Fernández-Montes, Cristina Farriols, Jose Luis Fírvida, Joan Santamaría, Guillermo de Velasco, Patricia Martín, Manuel Cobo, María Guirado-Risueño, Vanessa G. Jerviz-Guía, Carmen Perezagua-Marín, Rodolfo Chicas-Sett |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Constipation Palliative care medicine.drug_class Narcotic Antagonists Clinical Decision-Making Receptors Opioid mu Comorbidity Medical Oncology 03 medical and health sciences 0302 clinical medicine Opioid receptor Neoplasms medicine Humans Pharmacology (medical) Drug Interactions Practice Patterns Physicians' Intensive care medicine Adverse effect Evidence-Based Medicine business.industry Chronic pain Age Factors Cancer Disease Management Standard of Care Cancer Pain medicine.disease Clinical Practice 030104 developmental biology Treatment Outcome Oncology Opioid 030220 oncology & carcinogenesis Drug Therapy Combination medicine.symptom business medicine.drug |
| Zdroj: | Current treatment options in oncologyReferences and Recommended ReadingPapers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance. 22(3) |
| ISSN: | 1534-6277 |
| Popis: | Management of chronic pain is crucial to improve the quality of life of cancer and palliative care patients. Opioid-based treatments used to control pain can be prolonged over time. Unfortunately, constipation is one of the most disturbing adverse effects of long-term use of opioids. Opioid-induced constipation (OIC) occurs when opioids bind to the specific receptors present in the gastrointestinal (GI) tract, and can affect any patients receiving chronic opioid therapy, including cancer patients. The limited efficacy of laxatives to treat OIC symptoms prompted the search for new therapeutic strategies. Peripherally acting μ-opioid receptor antagonists (PAMORAs) have recently emerged as new effective drugs for OIC management due to their specific binding to enteric μ-receptors. Little information is available on the use of PAMORAs in real-life practice for OIC treatment in cancer patients. In this paper, a panel of experts specializing in cancer and palliative care pools their clinical experience with PAMORAs in cancer patients presenting OIC and highlights the importance of timing and choice of therapy in achieving prompt OIC management and benefitting patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink